Dr. DeAngelo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
450 Brookline Avenue
Dana-Farber Cancer Institute
Boston, MA 02115Phone+1 617-632-2645Fax+1 617-632-6771- Is this information wrong?
Summary
- Dr. Daniel DeAngelo is an oncologist in Boston, MA. He is currently the Chief of the Division of Leukemia at the Dana-Farber Cancer Institute and Brigham and Women's Hospital. He received his medical degree from Albert Einstein College of Medicine in 1993. He completed an internship and residency at the Massachusetts General Hospital and fellowship at the Dana-Farber Cancer Institute. He specializes in the treatment of patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelydysplastic syndromes, myeloproliferative neoplams, and systemic mastocytosis. He has more than 300 publications, reviews and chapters and over 39,000 citations with a h-index of 93.
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1996 - 1999
- Massachusetts General HospitalResidency, Internal Medicine, 1993 - 1996
- Albert Einstein College of MedicineClass of 1993
Certifications & Licensure
- FL State Medical License 2022 - Present
- MA State Medical License 1995 - 2026
- ME State Medical License 2023 - 2025
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- 506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Start of enrollment: 1998 Aug 01
- Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia Start of enrollment: 2005 Aug 01
- A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML) Start of enrollment: 2002 May 01
- Join now to see all
Publications & Presentations
PubMed
- Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients.Julia Keating, Donna S Neuberg, R Coleman Lindsley, Shai Shimony, Jacqueline S Garcia, Evan C Chen, Marlise R Luskin, Maximilian Stahl, Daniel J DeAngelo, Richard M Stone> ;Leukemia. 2024 Mar 27
- Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL.Yaqi Zhao, A Douglas Laird, Kathryn G Roberts, Rolla L Yafawi, Hagop M Kantarjian, Daniel J DeAngelo, Matthias Stelljes, Michaela Liedtke, Wendy Stock, Nicola Gökbuget...> ;Blood Advances. 2024 Mar 26
- Race/ethnic associations with comprehensive cancer center access and clinical trial enrollment for acute leukemia.Andrew M Brunner, Jesse J Plascak, Hajime Uno, Juan C Varela, Timothy R Rebbeck, Andrew Hantel, Marlise R Luskin, Richard M Stone, Christopher S Lathan, Daniel J DeAng...> ;Journal of the National Cancer Institute. 2024 Mar 22
- Join now to see all
Abstracts/Posters
- Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Na¥ve Patients with Relapsed or Refractory My...Daniel J. DeAngelo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Management of CAR T-Cell Toxicities: Concordance and Divergence between Healthcare Providers and Expert Consensus RecommendationsDaniel J. DeAngelo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Gene Expression Signature Predicts Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML): An Exploratory Biomarker Analysis from ENESTndDaniel J. DeAngelo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- New Data and Paradigms in ALL: Insights and Applications61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with R...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Ov...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Join now to see all
Press Mentions
- Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)December 11th, 2022
- Biotech Co.’s Shares Soar on Ph. 2 Hematology Trial ResultsJune 13th, 2022
- Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)June 11th, 2022
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
- Brigham and Women's HospitalBoston, Massachusetts
- Dana-Farber Cancer InstituteBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: